[1] Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: the good, the bad and the ugly effect[J]. Curr Med Chem, 2009, 16(25):3267-85. DOI: 10.2174/092986709788803312.
[2] Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin[J]. Clin Pharmacokinet, 1988, 15(1):15-31. DOI: 10.2165/00003088-198815010-00002.
[3] Peter S, Alven S, Maseko RB, et al. Doxorubicin-based hybrid compounds as potential anticancer agents: a review[J]. Molecules, 2022, 27(14):4478. DOI: 10.3390/molecules27144478.
[4] Tadokoro T, Ikeda M, Ide T, et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity[J]. JCI Insight, 2020, 5(9):e132747. DOI: 10.1172/jci.insight.132747..
[5] 肖献忠. 心血管内源性保护的分子机制研究[J]. 2002 . 肖献忠.心血管内源性保护的分子机制研究[C]//中国病理生理学会.国际心脏研究会(ISHR)中国分会第七届学术会议暨中国病理生理学会心血管专业委员会第十届学术会议论文集.中南大学湘雅医学院病理生理学教研室;,2002:64-66.
[6] 郭君婷,赵婷婷,叶斯木·塔拉甫别克,等. 基于Nrf2/HO-1信号通路调控的恰玛古多糖抗多柔比星心肌毒性的机制研究[J]. 药学学报,2024,59(4):930-938. DOI:10.16438/j.0513-4870.2023-1065.
[7] Ding M, Shi R, Fu F, et al. Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCε-Stat3 pathway[J]. J Adv Res, 2023, 47:151-162. DOI: 10.1016/j.jare.2022.07.002.
[8] Che Y, Wang Z, Yuan Y, et al. By restoring autophagic flux and improving mitochondrial function, corosolic acid protects against Dox-induced cardiotoxicity[J]. Cell Biol Toxicol, 2022, 38(3):451-467. DOI: 10.1007/s10565-021-09619-8.
[9] Wang T, Yuan C, Liu J, et al. Targeting Energy Protection as a Novel Strategy to Disclose Di'ao Xinxuekang against the Cardiotoxicity Caused by Doxorubicin[J]. Int J Mol Sci, 2023, 24(2):897. DOI: 10.3390/ijms24020897.
[10] 辛锦钰,张亚洁,古丽葛娜·萨吾尔,等. 天香丹对人脐静脉内皮细胞氧化损伤的保护作用研究[J]. 中医药学报,2022,50(1):18-22. DOI:10.19664/j.cnki.1002-2392.220005.
[11] 孙龙飞,古丽加玛力·尼亚孜,马文慧,等. 天香丹对动脉粥样硬化秽浊痰阻证ApoE(-/-)小鼠血清炎性细胞因子及NF-κB p65信号通路的影响[J]. 中国中西医结合杂志,2017,37(12):1471-1475. DOI:10.7661/j.cjim.20170901.260.
[12] 马学宽,古丽葛娜·萨吾尔,张华,等. 天香丹对冠脉微循环障碍大鼠Nrf2/ARE信号通路表达的影响[J]. 中国中西医结合杂志,2020,40(12):1489-1494. DOI:10.7661/j.cjim.20201102.052.
[13] Wu L, Wang L, Du Y, et al. Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity[J]. Trends Pharmacol Sci, 2023, 44(1):34-49. DOI: 10.1016/j.tips.2022.10.003.
[14] Sheibani M, Azizi Y, Shayan M, et al. Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches[J]. Cardiovasc Toxicol, 2022, 22(4):292-310. DOI: 10.1007/s12012-022-09721-1.
[15] Li X, Luo W, Tang Y, et al. Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction[J]. Redox Biol, 2024, 72:103129. DOI: 10.1016/j.redox.2024.103129.
[16] Liu C, Zhang M, Ye S, et al. Acacetin Protects Myocardial Cells against Hypoxia-Reoxygenation Injury through Activation of Autophagy[J]. J Immunol Res, 2021, 2021:9979843. DOI: 10.1155/2021/9979843.
[17] 彭玉娜,谭获,王颖超,等. 阿霉素导致兔血清肌钙蛋白T变化的实验研究[J]. 国际医药卫生导报,2007,13(16):13-15. DOI:10.3760/cma.j.issn.1007-1245.2007.16.004.
[18] Zhao MF, Sun LF, Xie XL, et al. Proteomic study of Tianxiangdan intervention in rats with myocardial ischemia[J]. J Physiol Pharmacol, 2022,73(2). DOI: 10.26402/jpp.2022.2.13.
[19] 李洋,程金凤,魏景迅,等. 氧化应激相关通路在阿霉素诱导心脏毒性中的作用[J]. 国际医药卫生导报,2024,30(20):3369-3372. DOI:10.3760/cma.j.issn.1007-1245.2024.20.005.
[20] 于晓霞,王洪梅,朱虹,等. 铁死亡参与阿霉素诱导的小鼠局灶节段性肾小球硬化[J]. 国际医药卫生导报,2021,27(15):2260-2263. DOI:10.3760/cma.j.issn.1007-1245.2021.15.010.
[21] Rawat PS, Jaiswal A, Khurana A, et al. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management[J]. Biomed Pharmacother, 2021, 139:111708. DOI: 10.1016/j.biopha.2021.111708.
[22] 花义同,侯长冉,张浩杰,等. 补骨脂素逆转GST-π介导的多药耐药的研究[J]. 国际医药卫生导报,2022,28(15):2084-2088. DOI:10.3760/cma.j.issn.1007-1245.2022.15.003.
|